What You Should Know:
– Medtronic (NYSE:MDT), a global leader in healthcare technology, announced it has received CE Mark approval for its groundbreaking BrainSense™ Adaptive deep brain stimulation (aDBS) technology in the European Union and…
Continue Reading
Adaptive deep brain stimulation (DBS) provides individualized therapy for people with Parkinson’s disease (PWP) by adjusting the stimulation in real-time using neural signals that reflect their motor state. Current algorithms, however, utilize condensed and…
Continue Reading
Improving health-related quality of life (QoL) is crucial for managing Parkinson’s disease. However, QoL outcomes after deep brain stimulation (DBS) of the subthalamic nucleus (STN) vary considerably. Current approaches lack integration of demographic, patient-reported,…
Continue Reading
Introduction
Parkinson’s disease (PD) affects millions worldwide, leading to debilitating symptoms that impact daily living. Traditional treatments offer some relief, but a “one-size-fits-all” approach limits their effectiveness. Recent advances in deep brain stimulation (DBS) and…
